EMA after Brexit? Prioritis continues to monitor the changes

The role of the EMA within the UK will continue until 31 December 2020. But the relationship remains uncertain from 01 January 2021.

What is certain during the transition period is:

  • During the transition period, EU pharmaceutical law will be applicable to the UK, although it will no longer participates in EU institutions.
  • Since 31st January 2020, no one representing the UK will participate in any EMA scientific committee meeting or sit on the Agency’s Management Board.

Full EMA article

While the role of the EMA in the UK remains uncertain beyond 2020, Prioritis will continue to monitor and track procedural changes for market access in the UK as part of our Prismaccess platform and consulting services.

For more information, feel free to contact us